Ignite Creation Date:
2025-12-24 @ 4:47 PM
Ignite Modification Date:
2026-01-02 @ 10:27 AM
Study NCT ID:
NCT07231250
Status:
NOT_YET_RECRUITING
Last Update Posted:
2025-11-19
First Post:
2025-11-13
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Glofitamab Plus Polatuzumab Vedotin and Zuberitamab in Patients With Newly Diagnosed Diffuse Large B-cell Lymphoma
Sponsor:
Li Zhiming
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2026-01-15
Start Date Type:
ESTIMATED
Primary Completion Date:
2026-09-15
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-09-15
Completion Date Type:
ESTIMATED
First Submit Date:
2025-11-13
First Submit QC Date:
None
Study First Post Date:
2025-11-17
Study First Post Date Type:
ESTIMATED
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-11-15
Last Update Post Date:
2025-11-19
Last Update Post Date Type:
ESTIMATED